The poster was referencing all trials (not a comparison with sarcoma versus RCC) saying that very few trials are stopped.
I asked a question about those two trials. Has nothing to do with comparing RCC versus sarcoma which are two, clearly different cell-lines. I'd like to know his line of thinking.